Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on LinkedIn:
“Second interim analysis confirms the benefit from addition of Pembrolizumab to CRT!!!
(Phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 Trial).
Pembrolizumab plus concurrent chemoradiotherapy (CRT), followed by pembrolizumab maintenance resulted;
- 32% reduction** in disease progression risk.
- 40% reduction** in second disease progression (PFS2) risk.
- 33% reduction** in risk of death.
PFS at 3 years 62.7% vs 54.5%.
OS at 3 years 82.6% vs. 74.8%.
Grade ≥3 treatment-related adverse events:
- 69.1% in the pembrolizumab group vs.
- 61.3% in the placebo group.
Immune-mediated adverse events:
- 39% in the pembrolizumab arm vs.
- 17% in the placebo arm (mostly grade 1 or 2).
Treatment-related deaths:
- 2 in each arm.
2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer.”
